FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - January 7, 2026 381 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR New targeted treatment for early breast cancer could reduce risk of... July 21, 2022 PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients... July 16, 2024 Telisotuzumab Vedotin Associated with Durable Responses in c-Met Protein–Overexpressing Non-Squamous EGFR-wild-type... August 5, 2024 ESMO Announces Winners of its Awards 2020 [ESMO Press Release] August 25, 2020 Load more HOT NEWS Online Retailer Chastised for Claiming Their Bra Reduces Risk of Breast... ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany NHS staff shortages: What’s needed to build a sustainable cancer workforce? No OS Benefit for Active Maintenance Treatment with Olaparib Relative to...
